← All trials
NCT05071417
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Oct 8, 2021
- Last posted
- Oct 8, 2021
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)Lead sponsor
- Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)Reponsible party - principal investigator
- Universidad Complutense de MadridStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.